Robert L Coffman

Summary

Publications

  1. pmc Vaccine adjuvants: putting innate immunity to work
    Robert L Coffman
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunity 33:492-503. 2010
  2. pmc TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
    Cristiana Guiducci
    Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
    Nature 465:937-41. 2010
  3. ncbi request reprint A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice
    John D Campbell
    Dynavax Technologies, Berkeley, California, USA
    Thorax 69:565-73. 2014
  4. pmc RNA recognition by human TLR8 can lead to autoimmune inflammation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710
    J Exp Med 210:2903-19. 2013
  5. doi request reprint Development of TLR inhibitors for the treatment of autoimmune diseases
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunol Rev 223:271-83. 2008
  6. ncbi request reprint Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 37:3582-6. 2007
  7. pmc PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 205:315-22. 2008
  8. pmc CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans
    John D Campbell
    Dynavax Technologies Corporation, Berkeley, California 94710, USA
    J Clin Invest 119:2564-76. 2009
  9. pmc Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 207:2931-42. 2010
  10. ncbi request reprint Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California, USA
    J Leukoc Biol 73:781-92. 2003

Collaborators

Detail Information

Publications22

  1. pmc Vaccine adjuvants: putting innate immunity to work
    Robert L Coffman
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunity 33:492-503. 2010
    ..However, the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens...
  2. pmc TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
    Cristiana Guiducci
    Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
    Nature 465:937-41. 2010
    ..These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs...
  3. ncbi request reprint A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice
    John D Campbell
    Dynavax Technologies, Berkeley, California, USA
    Thorax 69:565-73. 2014
    ..A single treatment has transient effects but a limited series of treatments has potential to achieve clinically meaningful sustained inhibition of allergic airway disease...
  4. pmc RNA recognition by human TLR8 can lead to autoimmune inflammation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710
    J Exp Med 210:2903-19. 2013
    ....
  5. doi request reprint Development of TLR inhibitors for the treatment of autoimmune diseases
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunol Rev 223:271-83. 2008
    ..We describe novel inhibitors of these receptors and provide evidence to support their use as novel therapeutic agents for autoimmunity...
  6. ncbi request reprint Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 37:3582-6. 2007
    ..These data demonstrate that in addition to its ability to block IFN-alpha, IRS 954 can reduce symptoms in a lupus model and thus represents a promising therapeutic agent for the treatment of SLE...
  7. pmc PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 205:315-22. 2008
    ..Thus, PI3K selectively controls type I IFN production by regulating IRF-7 nuclear translocation in human pDCs and could serve as a novel target to inhibit pathogenic type I IFN in autoimmune diseases...
  8. pmc CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans
    John D Campbell
    Dynavax Technologies Corporation, Berkeley, California 94710, USA
    J Clin Invest 119:2564-76. 2009
    ..These data demonstrate that ISS induce rodent-specific TNF-alpha-dependent toxicity that is absent in humans and reflective of differential TLR9 expression patterns in rodents versus humans...
  9. pmc Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 207:2931-42. 2010
    ..These data suggest that inhibitors of TLR7 and TLR9 signaling have potential therapeutic application for the treatment of interface dermatitis...
  10. ncbi request reprint Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California, USA
    J Leukoc Biol 73:781-92. 2003
    ....
  11. ncbi request reprint Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
    Holger Kanzler
    Dynavax Technologies, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
    Nat Med 13:552-9. 2007
    ..As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well...
  12. ncbi request reprint A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production
    Karen Fearon
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 33:2114-22. 2003
    ..These results describe a novel technique for formulating active, but very short, ISS oligodeoxynucleotide that allows for the dissection and characterization of minimal immunostimulatory CpG motifs...
  13. ncbi request reprint IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
    Omar Duramad
    Dynavax Technologies, 717 Potter St, Ste 100, Berkeley, CA 94710, USA
    Blood 102:4487-92. 2003
    ..The 3 distinct classes of ISS differed with respect to induction of PDC maturation and T-cell priming capacity. IL-10 regulated PDC activation but did not inhibit the subsequent T-cell-priming ability of PDCs already activated by ISS...
  14. ncbi request reprint Superior activity of the type C class of ISS in vitro and in vivo across multiple species
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California 94710, USA
    DNA Cell Biol 24:63-72. 2005
    ..In conclusion, we have shown CpG-C to exert several types of immune functions across multiple species, and this novel class is thus an attractive candidate for ISS-based therapeutic strategies...
  15. doi request reprint Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs
    Paul Sims
    Dynavax Technologies, Berkeley, CA 94710, USA
    Methods Mol Biol 517:415-40. 2009
    ....
  16. ncbi request reprint Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation
    Omar Duramad
    Dynavax Technologies, Berkeley, CA 94710, USA
    J Immunol 174:5193-200. 2005
    ..IRS can also inhibit a complex pathological response to ISS, as shown by protection from death after massive systemic inflammation induced by a CpG-containing oligodeoxynucleotides...
  17. pmc Nonhuman primate models of asthma
    Robert L Coffman
    Dynavax Technologies, Berkeley, CA 94710, USA
    J Exp Med 201:1875-9. 2005
    ..We advocate more extensive use of nonhuman primate asthma models to reconcile these differences between man and mouse...
  18. pmc Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 203:1999-2008. 2006
    ..This establishes that the primary determinant of TLR9 signaling is not valency but endosomal location and demonstrates a strict compartmentalization of the biological response to TLR9 activation in PDCs...
  19. pmc Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus
    Franck J Barrat
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 202:1131-9. 2005
    ..These inhibitors of TLR signaling thus represent novel therapeutic agents with potential for the treatment of lupus...
  20. pmc Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells
    Jason D Marshall
    Dynavax Technologies Corporation, 717 Potter Street, Suite 100, Berkeley, CA 94710, USA
    Nucleic Acids Res 31:5122-33. 2003
    ....
  21. pmc Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction
    Edith M Hessel
    Dynavax Technologies, Berkeley, CA 94710, USA
    J Exp Med 202:1563-73. 2005
    ..Thus, inhibition by ISS of allergic responses can be explained by two novel mechanisms that culminate in the inhibition of the principal sources of type 2 cytokines in the airways...
  22. ncbi request reprint Origins of the T(H)1-T(H)2 model: a personal perspective
    Robert L Coffman
    Dynavax Technologies, Berkeley, California 94710, USA
    Nat Immunol 7:539-41. 2006
    ..Robert L. Coffman recounts how his work on immunoglobulin E regulation along with data from Tim Mosmann on the functional heterogeneity of T cell clones led to the T helper type 1-T helper type 2 hypothesis...